Abstract:Background: Patients undergoing percutaneous coronary intervention react differently to antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of cardiac ischemic events. The goal of this study is to conduct a head-to-head comparison of the safety and effectiveness of intensified antiplatelet therapies (either double-dose clopidogrel [DOUBLE] or adjunctive cilostazol [TRIPLE]) and conventional strategy (STANDARD) in patients after percutaneous coronary intervention. Methods: In this single-center, randomized, controlled trial, we used thromboelastography, a platelet function test, to select 1078 patients undergoing percutaneous coronary intervention at high thrombotic risk and compared the intensified antiplatelet therapies with standard antiplatelet therapy. The primary outcome was the incidence of major adverse cardiac and cerebrovascular events at 18 months after percutaneous coronary intervention, defined as a composite of all-cause death, myocardial infarction, target vessel revascularization, or stroke. Bleeding Academic Research Consortium defined bleeding complications (types 1, 2, 3, or 5) were the safety end points. Results: The primary end point occurred in 52 patients (14.4%) in the STANDARD group, 38 patients (10.6%) in the DOUBLE group, and 30 patients (8.5%) in the TRIPLE group (hazard ratio, 0.720; 95% confidence interval, 0.474–1.094, DOUBLE versus STANDARD; hazard ratio, 0.550; 95% confidence interval, 0.349–0.866, TRIPLE versus STANDARD). No significant difference in the rates of major bleeding (Bleeding Academic Research Consortium grade≥3) was found in the DOUBLE group (3.34% versus 1.93% in STANDARD, P =0.133) and the TRIPLE group (2.53% versus 1.93% in STANDARD, P =0.240). The rate of Bleeding Academic Research Consortium–defined minor bleeding increased in the DOUBLE group (27.4% versus 20.3% in STANDARD, P =0.031), but not in the TRIPLE group (23.6% versus 20.3% in STANDARD, P =0.146). Conclusions: In patients with low responsiveness to clopidogrel, as measured by thromboelastography, the intensified antiplatelet strategies with adjunctive use of cilostazol significantly improved the clinical outcomes without increasing the risk of major bleeding. Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01779401.

Effects of Triple Antiplatelet Therapy on Patients Undergone Coronary Artery Stenting

The Effects of Post Coronary Stenting Triple Antiplatelet Therapies on Platelet Functions

Long-term effect of triple antiplatelet therapy for diabetic patients after percutaneous coronary intervention

The Application of Triple Antithrombotic Therapy Combined with Aspirin,Clopidogrel and Warfarin in Patients with Coronary Heart Disease

Effect of Different Doses of Cilostazol Intensive Antiplatelet Therapy on the Patients with High On-treatment Platelet Reactivity after Coronary Stent Implantation

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Optimal antiplatelet therapy after coronary stenting,a single-center randomized controlled pilot study

Cilostazol in Addition to Aspirin and Clopidogrel Improves Long-Term Outcomes after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes: A Randomized, Controlled Study

Efficacy and Safety of Cilostazol-Based Triple Antiplatelet Therapy Compared with Clopidogrel-Based Dual Antiplatelet Therapy in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter, Randomized, Open-Label, Phase 4 Trial

[A Clinical Trial of Using Antiplatelet Therapy to Prevent Restenosis Following Peripheral Artery Angioplasty and Stenting].

[Comparison on Long-Term Effects of Atorvastatin or Pravastatin Combined with Clopidogrel for Patients Undergoing Coronary Stenting: a Randomized Controlled Trial].

[Effects of Cilostazol on Long-Term Clinical Outcomes after Coronary Stenting].

Effects of Intensive Antiplatelet Therapy for Patients with High On-Treatment Platelet Reactivity after Coronary Stent Implantation

Study of atorvastatin and clopidogrel interaction in patients undergoing coronary stenting in a long-time treatment

Comparison of Cilostazol Versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke Who Underwent Intracranial or Extracranial Artery Stent Implantation

Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients with High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.

RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.

Dual and triple antithrombotic pharmacotherapy i n patients with coronary heart disease complicated with atrial fibrillation after percutaneous coronary intervention

A randomized trial of cilostazol versus ticlopidine for anti-platelet therapy after coronary artery stenting for prevention of restenosis

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Effectiveness of Combination of Cilostazol and Aspirin in Preventing Thrombosis after Interventional Neuroradiology Procedures